AIMT News and Press, Aimmune Therapeutics Inc. From 06/05/19

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of its Executive Management Team will participate in a fireside chat at the Goldman Sachs 40 th Annual Healthcare Conference on...

--APPEAL 2: Struggle to Avoid Accidental Peanut Exposure Negatively Impacts Quality of Life for Patients and Families-- --Phase 3 PALISADE Follow-on Study Analysis: Improvements in Quality of Life for Peanut-Allergic Patients after Continued AR101 Treatment-- Aimmune Therapeutics...

Aimmune Therapeutics (NASDAQ: AIMT ) announces results from ARC004, an open-label study of Phase 3 PALISADE trial. More news on: Aimmune Therapeutics, Inc., Healthcare stocks news, Read more ...

--Patients tolerated as much as 2,000 mg of peanut protein with fewer adverse events -- --Favorable ongoing and notable immunological changes observed over time-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening foo...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today presented topline results from the pivotal European Phase 3 ARTEMIS clinical trial, which it previously announced had met its primary endpoint, demonstratin...

– Full Results from Phase 3 ARTEMIS Study Will Be Featured – Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will present AR101 and patient quality of life data at...

-- 4 in 10 Teens believe they have a great or very great chance or certainty of dying from accidental exposure -- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced results of a new study...

One, which I mention several times elsewhere, is the need for patience if big profits are to be made from investment. Put another way, it is often easier to tell what will happen to the price of a stock than how much time will elapse before it happens. The other is the inherently deceptive ...

Allergenic Products Advisory Committee (APAC) of FDA will review Aimmune Therapeutics' (NASDAQ: AIMT ) BLA for AR101 at its meeting scheduled for September 13. More news on: Aimmune Therapeutics, Inc., Healthcare stocks news, Read more ...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt, will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 21, 20...